| Expression pattern: |
UP |
| Associated gene: |
Smad2, Smad4, EGFR |
| Associated microRNA: |
miR-219a-5p |
| Biological function: |
Promotes gallbladder cancer cell viability and migration, promotes tube formation of HDLECs, and inhibits apoptosis. |
| Molecular mechanism: |
Acts as a miRNA sponge for miR-219a-5p, thereby enhancing Smad2/Smad4 (TGF-beta/Smad signaling) and EGFR expression. |
| Biological pathway or process: |
TGF-beta/SMAD (promotes); EGFR (promotes); apoptosis (inhibits); proliferation (promotes); migration (promotes); angiogenesis (promotes) |
| Detected method: |
Q
S
|
| Validation methods: |
RT-qPCR; RNA-seq; Transfection; MTT; Transwell Assay; Annexin V/PI Flow Cytometry; Tube Formation Assay; Western Blot; Bioinformatics Analysis; Survival Analysis |
| Clinical significance: |
circMTO1 expression was higher in GBC vs healthy individuals; high circMTO1 expression was associated with shorter overall survival and with advanced stage. |
| Description: |
In gallbladder cancer, circMTO1 is up-regulated and functions as an oncogenic circRNA. It sponges miR-219a-5p, leading to increased Smad2/Smad4 (TGF-beta/Smad signaling) and EGFR expression, thereby promoting viability/migration and tube formation while suppressing apoptosis; high expression correlates with poorer overall survival and more advanced stage. |
| Confidence score: |
0.6111 |